Key result
This state-of-the-art review highlights that VTE management in lung cancer requires specific risk assessment tools beyond the Khorana score and tailored thromboprophylaxis strategies.
Why the study?
Venous thromboembolism is common and life-threatening in lung cancer, but management presents specific challenges and the value of standard risk scores like the Khorana score remains controversial in this population.
This review highlights the specific nuances of VTE management in lung cancer patients, emphasizing the need for tailored risk assessment and thromboprophylaxis strategies.
May support tailored VTE risk assessment in lung cancer; leaves open prospective validation before routine adoption.
Venous thromboembolism (VTE) is common and life-threatening in patients with lung cancer. Management of VTE is critical for patients with lung cancer. Risk assessment, thromboprophylaxis and treatment of VTE constitute the core issues of VTE management in patients with lung cancer. Although its overall principles should follow recommendations in authoritative guidelines, VTE management in patients with lung cancer may be slightly special in some specific aspects. Despite the extensive validation of Khorana score for patients with all cancer types, its value in VTE risk assessment of patients with lung cancer is controversial. It is important to determine the VTE risk assessment score that can accurately and specifically assess the VTE risk of patients with lung cancer. Clinical practice patterns of thromboprophylaxis may vary by cancer types, since different sites of cancer may have different levels of VTE risk. To understand the thromboprophylaxis specific for lung cancer is of vital importance for patients with lung cancer. Although it is essential to comply with authoritative guidelines, the duration and timing of initiation of thromboprophylaxis in surgical patients with lung cancer may need further study. Taken together, the purpose of this review is to provide an overview of state-of-the-art VTE stewardship specific for patients with lung cancer.
No takes yet. Share an insight, caveat, or question.
Xiong et al. (2023) conducted a review in Venous thromboembolism in patients with lung cancer. VTE management (risk assessment, thromboprophylaxis, and treatment) was evaluated. This state-of-the-art review highlights that VTE management in lung cancer requires specific risk assessment tools beyond the Khorana score and tailored thromboprophylaxis strategies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: